Elevated Expression of ISG15 in Tumor Cells Interferes with the Ubiquitin/26S Proteasome PathwayShyamal D. Desai, Leroy F. Liu, Arthur L. Haas et al.|Cancer Research|2006Cited by 194
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnosticSunyu Kang, Eric H. Rubin, Kevin Gergich et al.|Annals of Oncology|2017Cited by 106
A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid TumorsScot Ebbinghaus, Lisa A. Hammond, Eric H. Rubin et al.|Clinical Cancer Research|2005Cited by 49
Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumorsL. A. Hammond, Eric K. Rowinsky, Francis Ruvuna et al.|Journal of Clinical Oncology|2004Cited by 8
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of PembrolizumabRobert Kester, Eric H. Rubin, Sunita Zalani et al.|Drugs|2024Cited by 2